Table 1. Absolute numbers and percentages of symptomatic and symptom-free animals used in this study.
| genotype | n | Age (days) range1; median |
manipulation | mice with GIST- like tumors |
mice with other abnormalities |
healthy |
|---|---|---|---|---|---|---|
| LysMcre +/− | 9 | 583-670; 604 | - | - | - | 9 |
| Ptch flox/flox | 17 | 96-524; 324 | - | - | - | 17 |
| Ptchflox/floxLysMcre+/− | 18 | 398-693; 640 | - | - | - | 18 |
| Ptchflox/floxLysMcre+/− | 34 | 116-555; 206 | - | 28 (82%) | 1 | 5 |
| Ptchflox/floxLysMcre+/− | 7 | 127 | 0.1g/kg/d imatinib orally starting at 8 weeks of age for 10 weeks |
7/7; tumor multiplicity2: 2.6±1.3 |
- | - |
| Ptchflox/floxLysMcre+/− | 6 | 127 | vehicle (200 μl PBS) orally starting at 8 weeks of age for 10 weeks |
6/6; tumor multiplicity2: 5.2±1.7 |
- | - |
| Rag−2−/−γc−/− | 5 | 253-323; 323 | transfer of Ptchflox/floxLysMcre+/− bone marrow at 8 weeks of age |
- | - | 5 |
| Rag-2−/− γ c−/− | 5 | 306-323; 323 | transfer of Ptchflox/flox bone marrow at 8 weeks of age |
- | - | 5 |
1
from birth on
2
mean ± SD